Actionable news
All posts from Actionable news
Actionable news in PETX: Aratana Therapeutics, Inc.,

Credit Suisse Weighs in on Aratana Therapeutics (PETX) 2Q Earnings; All Eyes on Galliprant

Credit Suisse analyst Erin Wilson weighed in on Aratana Therapeutics (NASDAQ:PETX), after the pet biopharmaceutical company reported second-quarter results, posting EPS of ($0.48), below Wilson’s projection of ($0.39). However, for Wilson, pet biotech companies play a different game, and the earnings rules don’t apply as “meaningful catalysts.” With sharp focus instead on new developments on the rise, Wilson reiterates a Buy rating with a price target of $11, marking a 30% increase from where the stock is currently trading.

Importantly of note in the works is a $38 million contribution from collaborator Elanco (Eli Lilly), which paired with higher operating expenses and an impairment charge of $3 million will offset better product revenues. As such, reflecting the...